ATRX (Adhera Therapeutics) Cyclically Adjusted PB Ratio: (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRX Adhera Therapeutics Inc ATRX
12 GF Score
Price $0.00
View Full Analysis

What is Adhera Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adhera Therapeutics  (OTCPK:ATRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Adhera Therapeutics Cyclically Adjusted PB Ratio Related Terms


Adhera Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Adhera Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Cyclically Adjusted PB Ratio Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.02 0.00 0.00

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ATRX vs PKBO, ARDS, NYMXF: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Adhera Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Cyclically Adjusted PB Ratio falls into.


ATRX
12GF Score
Adhera Therapeutics Inc ATRX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adhera Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Adhera Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Adhera Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-5.091/307.7890*307.7890
=-5.091

Current CPI (Sep. 2023) = 307.7890.

Adhera Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 -83.106 233.049 -109.759
201403 -57.008 236.293 -74.257
201406 -26.000 238.343 -33.576
201409 -79.586 238.031 -102.910
201412 -34.148 234.812 -44.761
201503 -28.523 236.119 -37.181
201506 -18.902 238.638 -24.379
201509 -3.030 237.945 -3.919
201512 1.892 236.525 2.462
201603 10.178 238.132 13.155
201606 7.215 241.018 9.214
201609 9.416 241.428 12.004
201612 7.169 241.432 9.139
201703 7.049 243.801 8.899
201706 5.028 244.955 6.318
201709 3.255 246.819 4.059
201712 0.852 246.524 1.064
201803 -1.510 249.554 -1.862
201806 21.584 251.989 26.364
201809 10.877 252.439 13.262
201812 5.441 251.233 6.666
201903 0.710 254.202 0.860
201906 -4.624 256.143 -5.556
201909 -9.915 256.759 -11.886
201912 -18.208 256.974 -21.809
202003 -21.792 258.115 -25.986
202006 -24.120 257.797 -28.797
202009 -25.831 260.280 -30.546
202012 -26.570 260.474 -31.396
202103 -26.641 264.877 -30.957
202106 -27.742 271.696 -31.427
202109 -27.954 274.310 -31.366
202112 -29.536 278.802 -32.607
202203 -29.141 287.504 -31.197
202206 -6.336 296.311 -6.581
202209 -6.899 296.808 -7.154
202212 -7.019 296.797 -7.279
202303 -7.264 301.836 -7.407
202306 -5.936 305.109 -5.988
202309 -5.091 307.789 -5.091

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adhera Therapeutics Business Description

Address 8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score

Get the complete analysis for ATRX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price